docHepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024
download 
Report Transcription
Hepatitis B Virus (HBV) Therapeutics Market to Expand at a modest Compound Annual Growth Rate (CAGR) of 2.4% Up to 2024 The global hepatitis B market, which is set to experience limited growth from $2.4 billion in 2014 to $3 billion by 2024, is being stymied by the persistence of low diagnosis and treatment rates, according to research. Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. This report provides analysis of the hepatitis B therapeutics space across the eight major markets of the US, France, Germany, Italy, Spain, the UK, Japan, and China, with annualized market data from 2014 and forecast to 2024. It discusses strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the hepatitis B therapeutics market. Browse Detailed Toc, Tables, Figures, Charts and Companies Mentioned in Hepatitis B Virus (HBV) Therapeutics Research Report at- http://www.absolutereports.com/pharmapoint-hepatitisb-virus-hbv-therapeutics-global-drug-forecast-and-market-analysis-to-2024-10112599 Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance. Ask for Discount on Hepatitis B Virus (HBV) Research Report at – http://www.absolutereports.com/enquiry/request-discount/10112599 Scope +1 408 520 9750 Overview of chronic HBV infection, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options. Top line HBV therapeutics market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. www.absolutereports.com Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the HBV therapeutics market. Request sample PDF of this report at - http://www.absolutereports.com/enquiry/requestsample/10112599 In addition, Hepatitis B Virus (HBV) Therapeutics Report anticipates that opportunities centered on the development of antivirals with novel MOAs, which can improve the efficacy of existing drugs, will exist for current and future players in the HBV therapeutic marketplace for the duration of the forecast period. Major key players covered in this report are Gilead, Bristol-Myers Squibb, Roche, Merck, GSK, Novartis, Arrowhead Research and Globe Immune. About Absolute Report: Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters. Contact– Mr. Ameya Pingaley Absolute Reports +1-408 520 9750 Email – sales@absolutereports.com Website: www.absolutereports.com +1 408 520 9750 www.absolutereports.com
Similar documents
Medtronic plc, Bioventus LLC and Depuy Companies Dominate the UK Orthobiologics Market Report
The orthobiologics market in the UK is expected to be driven by patient demographics, the development of novel product designs, increasing patient awareness, increasing participation in sports related activities, and a rising incidence of road accidents. The data in the report is derived from dynamic market forecast models.
Latest Report: Glioblastoma Treatment Market Will Expand Fivefold to $3.3 Billion at a CAGR of 17.4% by 2024
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid Compound Annual Growth Rate (CAGR) of 17.4% according to a leading research and consulting firm. Of the 7MM, Japan will see the most impressive relative growth, with sales expanding from $47 million in 2014 to $268 million in 2024, representing a CAGR of 19.7%.
Ventricular Fibrillation: Global Industry Analysis, Trends, Market Demands, Segment and Forecast
Ventricular Fibrillation- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India.
France Orthopedic Prosthetics Procedure report to 2021, Market Shares, Research Report, Industry Analysis, Forecast Opportunity
prosthesis is a functional replacement for an amputated or congenitally malformed or missing limb. Prosthetists are responsible for the prescription, design and management of a prosthetic device. In most cases, the prosthetist begins by taking a plaster cast of the patient's affected limb. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market segments - Lower Extremity Prosthetics and Upper Extremity Prosthetics.
Human Immunodeficiency Virus (Hiv) Therapeutics Market Worth Will Be $15 billion in Sales by 2023
The global HIV therapeutics market was worth approximately $14 billion in 2013, and it is expected to rise a total of $15 billion in sales by 2023, at a Compound Annual Growth Rate (CAGR) of 0.9%. These sales are expected to come predominantly from the US market, as financial austerity measures remain a primary barrier to the growth of the HIV market in the other countries covered in this report.
Latest Research Report on Medical Equipment Monthly Deals Analysis: JANUARY 2016 - M&A and Investment Trends
Medical Equipment Monthly Deals Analysis: JANUARY 2016 report provides detailed information on M&As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in January 2016.
Recent Research: Respiratory Syncytial Virus Treatment Market Will Surpass $2.3 Billion by 2024
According to a leading research and consulting firm, The Global Respiratory Syncytial Virus (RSV) treatment market will expand to unprecedented levels over the next decade, rising from approximately $640 million in 2014 to over $2.3 billion by 2024, representing an impressive Compound Annual Growth Rate (CAGR) of 29.9%.
Latest Research: US Will Remain Hernia Repair Market Leader by 2021
The overall US hernia repair market is expected to rise to approximately $1.2 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 4%. It was valued at approximately $875 million in 2014. The US has a higher adoption of expensive meshes in general, and procedure volume will go up by 1% annually. For example, the majority of umbilical hernia repairs are performed with composite meshes, which contribute to a higher market valuation.
Prophylactic Hepatitis B Virus Vaccines Market : Global Industry Analysis and Forecast 2016 - 2024
The prophylactic hepatitis B virus vaccines market is expected to grow remarkably during the forecast period due to increasing prevalence and incidence of hepatitis B infection, increasing public awareness (Patient Education Programs), government initiatives for promotion and creating awareness about prophylactic hepatitis B vaccines.
Diagnosed Prevalent Cases of Fabry Disease in The 7MM Will Rise at an AGR of 7.71% By 2024
The report,” Fabry Disease - Epidemiology Forecast to 2024 “provides an overview of the risk factors, comorbidities/manifestations, and the global and historical epidemiological trends for Fabry disease in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of Fabry disease in these markets, segmented by age and sex.